Index

Action-readiness. See Emotion, and action-readiness
ADM. See Antidepressant medication
Affect
biased, 60, 61
and decision-making, 4–5, 49–54, 63
and evaluative conditioning, 53
evaluative utility of, 39, 58–59
as evidence for the existence of triggering events, 4, 40, 41–44, 54
as evidence for the value of triggering events, 4, 40, 44–46, 54
evidential value of, 5, 39, 54–64
evidential value in depression, 5, 54, 94
heuristic, 53, 54
and the materiality of triggering events, 4, 39–46, 62–64 (see also Material facts)
and motivation, 46–49, 54, 63
Agency, 10, 12–13
authorization condition for, 18
Allen, Nicholas, 105
Amygdala, 44, 52, 116, 117, 128, 131
Andersen, Susan, 67
Angermeyer, Matthias, 84
Antidepressant medication (ADM)
and autonomy promotion in depression. See Autonomy, promotion with antidepressant medication (ADM)
and beliefs about depression causation, 89–90
cognitive neuropsychological model of action, 111, 116
direct to consumer advertising (DTCA) of, 7, 88, 165–166
efficacy in depression, 3, 153
mode of action in depression, addressing information processing biases, 109–111
mode of action in depression, addressing stressors, 127–130
and restricted affective range in depression, 6, 113–117
and treatment statistics in depression, 1–2, 87
Antonuccio, David, 161
Australian Pharmaceutical Benefits Scheme, 87
Autonomy
and the best interests of patients, 22, 31, 32
and chronic disease self-management. See Chronic disease self-management
dispositional, 12
and the evidential value of affect, 54–64
and grounds for belief, 16
impairment in depression, the role of information processing biases, 74–77
and justified beliefs, 15–23
Autonomy (cont.)
and justified beliefs about
depressogenic stressors, 3, 82–95
and justified beliefs about the
evidential value of affect, 54–64,
75–77
and material facts, 4, 20–21
and the materiality of depressogenic
stressors, 82–85
normative force of, 4, 35–37, 146
occurrent, 11–12
and a particular patient standard of
understanding, 20
and personhood, 37
and the physician’s duty of
beneficence, 146, 147, 157
physician’s duty to promote in
depression, 143–155
and the problem of authority, 11
professional, 7, 158–160
promotion through cognitive
behavioral therapy (CBT), 3,
107–109, 111–118, 124–127,
130–141
promotion with antidepressant
medication (ADM), 111–118,
130–141
as a proper goal of medicine. See
Proper goals of medicine
and rational assessment of beliefs, 14
respect for, versus promotion of,
157–158
summary statements of, 3–4, 13, 23,
131
and testimony, 17
theories of, epistemic, 4, 15–18
theories of, hierarchical, 3, 10–11, 13,
19
theories of, historical, 3, 11, 12, 19
theories of, life-plan, 3, 11–12, 13, 19
theories of, reasons-responsive, 3, 12,
13, 19
and true beliefs, 15–16

value of, instrumental, 4, 30–32,
146
value of, intrinsic, 4, 33–35, 146

Baird, Grayson, 86
Ball, Harriet, 92
Bayles, Michael, 158, 159
BDNF. See Brain derived neurotrophic
factor
Beauchamp, Tom, 17, 20, 21, 62, 133,
134
Beck, Aaron, 67, 109
Beecher, Henry, 31, 32
Beliefs. See Autonomy
Beneficence, 7, 143, 159, 160, 162–164
duty of, 146, 147, 151
Beneficent authoritarianism, 24
Benson, John, 17, 57
Bentz, Bret, 102
Berlin, Isaiah, 10
Berofsky, Bernard, 13–14
Best interests. See also Prudential value
and autonomy, 22, 31–32
and duty of care, 147, 162, 163
and informed consent, 31
and medical paternalism, 24
and refusal of medical treatment, 34
Beyondblue guidelines for treatment of
depression in primary care, 3, 165.
See also Depression, guidelines for
treatment of
Blumner, Kate, 85
Brain derived neurotrophic factor
(BDNF), 80, 109
Brandt, Richard, 33
Brock, Dan, 26, 27, 28
Brown, Charlotte, 85
Brown, George, 79
Buchanan, Allen, 25, 26, 27, 28
Buss, Sarah, 18

Callahan, Daniel, 155
Campbell, Lynlee, 70
Care, duty of, 147, 148, 150, 162, 163
Carson, Richard, 73
Caspi, Avshalom, 81
CBSM. See Cognitive behavioral stress management
CBT. See Cognitive behavioral therapy
Christman, John, 11, 12, 19
Chronic disease self-management, 7, 143, 149
Clore, Gerald, 54–55, 57
Cognitive behavioral stress management (CBSM), 120, 140
Cognitive behavioral therapy (CBT) and autonomy promotion in depression. See Autonomy, promotion through cognitive behavioral therapy (CBT)
behavioral component of, 68, 106–107
collaborative empiricism in, 100, 112, 127
cost of, 160–161
debiasing in, 6, 99–105,
duration of treatment, 90
efficacy in depression, 2, 67, 153
and metacognitive awareness, 77, 105–107
mindfulness approach in, 77, 105–107, 126
mode of action in depression, addressing information processing biases, 98–107
mode of action in depression, addressing stressors, 119–124
moral obligation for physicians to provide, 6, 143–167
and reattribution, 100, 104
sudden gains in, 103
treatment statistics in depression, 87–88
Competence, 179n46
Consent, informed
and counselling, 144–148
and material information, 20–21
(See also Material facts)
as a model for epistemic autonomy, 18–23
and operative outcomes, 30–32
and patients’ best interests, 31, 32
Coping theory, 120–124
Core relational themes, 45
Cost-benefit utility of depression treatments, 7, 160–162, 166
Counselling
antenatal, 143–145
and gender reassignment surgery, 145
Genetic, 145, 147
DALY. See Disability adjusted life year
Damasio, Antonio, 48, 49, 50, 51, 52
Deacon, Brett, 86
Debiasing. See Cognitive behavioral therapy, debiasing in
Depression
attentional biases in, 68, 71
autonomy impairment in
(see Autonomy, impairment in depression, the role of information processing biases)
availability biases in, 68–71
beliefs about causation, 84–87
biased information processing in, 68–71, 99, 110
biased retrievability of instances in, 69
biological models of causation, 87–90
burden of disease in, 1
and cognitive distortions, 67, 99, 100
cognitive theory of, 65–68
contingency judgment task and, 72
cortisol, causal role in, 80, 81, 120, 128, 129, 140
and Cushing’s syndrome, 129
definition of, 66
dependent events in, 72
Depressive realism. See Depression, and depressive realism
DeRubeis, Robert, 107, 117
Desires
non-instrumental, 33
properties of, consistent with autonomy, 4, 9–15
rational assessment of, 13–14
De Sousa, Ronald, 42, 45
Diabetes, 149

Diabetes self-management education (DSME), 149, 150
Diagnostic and Statistical Manual of Mental Disorders (DSM), 66, 100
Disability adjusted life year (DALY), 161
Down syndrome, 145, 146, 147
DSM. See Diagnostic and Statistical Manual of Mental Disorders
DSME. See Diabetes self-management education
DTCA. See Antidepressant medication, direct to consumer advertising of
Dunn, Barnaby, 52
Dunning, David, 73
Dworkin, Gerald, 10

Ekman, Paul, 43
Elliot, the case of, 49–50
Emotion. See also Affect
and action-readiness, 46
and certainty of related appraisals, 56, 61
and decision-making (see Affect, and decision-making)
elicitors of, 43
as evidence (see Affect)
as indicators of salience, 42
and intelligence, 55, 167
and motivation, 4, 46–49, 54
and physiological change, 47–48
theories of, appraisal, 4, 44, 121
theories of, evaluative, 4, 40, 164
theories of, cognitivist, 41
theories of, judgmentalist, 41
Emotional blunting, 114. See also
Antidepressant medication (ADM), and
restricted affective range in depression
Emotional intelligence. See Emotion, and intelligence
Epistemic luck, 15, 16
Ethical theories, 35–37
Index

Evaluative conditioning, 53, 58
Evidence, 40, 41
Explanation bias, 102

Faden, Ruth, 17, 20, 21, 62, 133, 134
Feeling. See Affect
Feinberg, Joel, 28, 29
Fischer, John, 12
Five-hydroxytryptamine (5-HT). See Serotonin
Five-hydroxytryptamine transporter (5-HTT) gene, 81, 82, 129, 136
Folkman, Susan, 121
France, Christopher, 88
Frankfurt, Harry, 10
Frijda, Nico, 46, 47, 49, 56, 62
Fu, Tiffany, 73

Glover, Jonathan, 33

Hamilton Rating Scale for Depression, 2, 169
Hammen, Constance, 78
Harkness, Kate, 79, 86
Harmer, Catherine, 109, 110, 111, 113, 116, 117
Hartrick, Gwen, 89
Hayes, Brett, 101
Health, definitions of, 155–156
Hesketh, Beryl, 101

Heuristic
affect (see Affect, heuristic)
availability, 68–71, 102, 104
better safe than sorry, 59
and dual process theories, 61
expert authorship, 61
how do I feel about it?, 54–55
simulation, 71, 102
visual clarity and distance, 60
Hippocampus, 80, 81, 116, 128, 129, 131, 136, 140
Hirt, Edward, 101, 102
Hollon, Steven, 107

Horwitz, Allan, 66
Hsee, Christopher, 45

IGT. See Iowa gambling task
Informed consent. See Consent, informed
Insula, 48, 51
Interpersonal therapy (IPT), 3, 79, 87, 98, 120
Iowa gambling task (IGT), 50, 51, 52, 108
IPT. See Interpersonal therapy

James, William, 43, 47, 48, 49
Kahneman, Daniel, 68, 69, 70, 71
Kant, Immanuel, 37
Kendler, Kenneth, 77, 78, 81, 82, 129, 136
Kessler, Ronald, 78
Knutson, Brian, 113
Kramer, Peter, 128, 129, 135, 136, 137, 138
Kunreuther, Howard, 45
Lauber, Christoph, 84
Layard, Richard, 162
Lazarus, Richard, 44, 45, 54, 62, 121, 122, 124
Leykin, Yan, 89
Liberty, 12
negative and positive, 10, 13
Luty, Suzanne, 79

MacLeod, Andrew, 70, 71, 102
MacLeod, Colin, 70
Maia, Tiago, 51
Marcus, Steven, 85
Markman, Keith, 101, 102
McClelland, James, 51
McEwen, Bruce, 120
Material facts, 3, 20, 125, 133, 145
Matschinger, Herbert, 84
Mayer, John, 55
MBCT. See Mindfulness-based cognitive therapy
Meichenbaum, Donald, 123
Mele, Alfred, 11
Mental Health America, 86
Mesquita, Batja, 56
Mill, John Stuart, 30
Mindfulness-based cognitive therapy (MBCT), 98
Mitchell, Philip, 79
Monroe, Scott, 79, 86
Moral theories. See Ethical theories

Neuroresilience, 129, 136
Nolen-Hoeksema, Susan, 126

Ohman, Arne, 44
Olff, Mark, 87
Opbroek, Adam, 114

Paradigm scenarios, 42, 45
Parity of reasoning, and the moral obligation to provide cognitive behavioral therapy in depression, 6–7, 143, 144–151
Paternalism, 4, 24–30
Pellegrino, Edmund, 24
Personal autonomy. See Autonomy
Personhood, 37, 146, 147
Pessimism, unrealistic, in depression, 6, 65, 68, 70, 71, 72, 77, 107, 108, 112
Pham, Michel, 55
Pirraglia, Paul, 161
Prevention of harm argument, 26
Price, Jonathan, 114
Problem-solving, 6, 123, 130, 131
Problem-solving therapy, 87, 90, 98, 120, 124
Professional autonomy. See Autonomy, professional
Proper goals of medicine, 7, 155–158

Proportionality, principle of, 143, 151–155, 163
Prudential value, theories of, 27–28
Psychosocial stressors. See Stressors
Psychotherapy, 2, 98, 164–167. See also Cognitive behavioral stress management (CBSM); Cognitive behavioral therapy (CBT); Interpersonal therapy (IPT); Mindfulness-based cognitive therapy (MBCT); Problem-solving therapy

Quality adjusted life year (QALY), 161

Ravizza, Mark, 12
Relevant facts, 20–22
Robinson, Jenefer, 41
Rogers v Whitaker, 20
Rushton, John, 135

Salience. See Emotions, as indicators of salience
Sapolsky, Robert, 80
Schema, 69, 70. See also Depression, and schema
Schreiber, Rita, 89
Schwarz, Norbert, 53, 59
Serotonin, 80, 82, 109, 190n80
Serotonin transporter gene. See Five-hydroxytryptamine transporter (5-HTT) gene
Shared and nonshared environment, 135–136
Simmons, Julian, 114
Skin conductance, 50–52
Slovic, Paul, 53, 59
SMH. See Somatic marker hypothesis
Soares, Joaquim, 44
Social phobia, 137–139
Somatic marker hypothesis (SMH), 48, 52
Srinivasan, Janaki, 85
Story, Amber, 73
Stressors. See Antidepressant medication (ADM); Autonomy; Depression; Cognitive behavioral therapy
Strupp, Hans, 98
Substituted judgment, 28–29

Taijin kyofusho, 43
Teasdale, John, 77, 104, 105
Thomasma, David, 24
Trier social stress test, 120
Tversky, Amos, 68, 69, 70, 71

Ultimatum game, 52
Utilitarianism. See Ethical theories
Utility, 30, 36

van’t Wout, Mascha, 52
Vaughn, Leigh Ann, 71
Ventromedial prefrontal cortex (VMPFC), 50, 51

Wakefield, Jerome, 66
Watson, Gary, 11
Weary, Gifford, 71

Young, Robert, 10, 11, 18, 33, 34, 35